Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Fluphenazine decanoate: a clinical problem?

L B Inderbitzin¹, R R Lewine, B A Gloersen

¹Department of Psychiatry, Emory University School of Medicine, Atlanta, GA.

The American Journal of Psychiatry

|January 1, 1989

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Toluene induced hypokalaemia: case report and literature review.

Emergency medicine journal : EMJ·2001

Same author

Fantasy and psychoanalytic discourse.

The International journal of psycho-analysis·2001

Same author

Racial effects on neuropsychological functioning in schizophrenia.

The American journal of psychiatry·2000

Same author

Suggestion and psychoanalytic technique.

Journal of the American Psychoanalytic Association·2000

Same author

Regression and psychoanalytic technique: the concretization of a concept.

The Psychoanalytic quarterly·2000

Same author

Age at onset and sex differences in corpus callosum area in schizophrenia.

Schizophrenia research·2000

Same journal

2026 Annual Meeting: President-Elect Address.

The American journal of psychiatry·2026

Same journal

2026 Annual Meeting: CEO and Medical Director's Address.

The American journal of psychiatry·2026

Same journal

Reports to the Membership.

The American journal of psychiatry·2026

Same journal

Convergent Metabolic Dysregulations But Divergent Contributing Pathways Across Severe Mental Disorders: The Power of Combining Genetics and Metabolomics.

The American journal of psychiatry·2026

Same journal

2026 Annual Meeting: Presidential Address.

The American journal of psychiatry·2026

Same journal

Represcribing Previously Used Antipsychotics: Response to So.

The American journal of psychiatry·2026

See all related articles

Long-acting injectable fluphenazine decanoate may lead to higher antipsychotic medication doses in some schizophrenia patients. This study found higher chlorpromazine equivalent doses in patients on injectable versus oral antipsychotics.

Area of Science:

Psychiatry
Pharmacology
Clinical Medicine

Background:

Schizophrenia treatment often involves antipsychotic medications.
Long-acting injectable (LAI) antipsychotics offer an alternative to daily oral dosing.
The impact of LAI antipsychotics on overall medication dosage requires further investigation.

Purpose of the Study:

To compare the total antipsychotic medication dosage in schizophrenic patients receiving fluphenazine decanoate versus oral antipsychotics.
To identify potential differences in medication burden between injectable and oral antipsychotic treatment in schizophrenia.

Main Methods:

Retrospective chart review of 40 randomly selected schizophrenia patients.
Comparison of 20 patients on fluphenazine decanoate with 20 patients on oral antipsychotics only.

Related Experiment Videos

Calculation of chlorpromazine equivalent doses to standardize antipsychotic exposure.

Main Results:

The fluphenazine decanoate group exhibited a significantly higher mean chlorpromazine equivalent dose (2010 +/- 836) compared to the oral medication group (373 +/- 384).
No significant differences were observed in other studied variables between the two groups.
This suggests a potential for increased overall antipsychotic load with fluphenazine decanoate.

Conclusions:

The use of fluphenazine decanoate may be associated with a higher overall antipsychotic dose in a subset of schizophrenia patients.
Clinicians should consider total medication burden when prescribing long-acting injectable antipsychotics.
Further research is warranted to understand the implications of higher antipsychotic doses in patients on injectable formulations.